Fleroxacin API Manufacturers & Suppliers

Fleroxacin (CAS number 79660-72-3) is a synthetic antimicrobial agent classified within the fluoroquinolone subclass of quinoline carboxylic acids. It exhibits broad-spectrum antibacterial activity primarily through potent inhibition of bacterial DNA gyrase, a type II topoisomerase enzyme essential for DNA supercoiling necessary for replication and transcription.

The primary pharmacological action of fleroxacin involves disruption of bacterial DNA replication processes by inhibiting the DNA-supercoiling activity of DNA gyrase and DNA topoisomerase IV. This inhibition results in impaired DNA repair and recombination, leading to bacterial cell death. Unlike some fluoroquinolones, fleroxacin does not inhibit cytochrome P450 enzyme CYP1A2, suggesting a lower potential for certain drug-drug interactions mediated by this pathway.

Fleroxacin is categorized experimentally and has not achieved widespread regulatory approval for clinical use. It is noted for its potential as a systemic anti-infective agent. As a member of the fluoroquinolone class, it shares pharmacodynamic properties common to this group, including activity against a broad array of Gram-positive and Gram-negative bacteria.

Pharmacokinetic data on absorption, distribution, metabolism, and excretion (ADME) parameters for fleroxacin remain limited in the public domain due to its experimental status. Caution should be exercised as fluoroquinolones as a class have been associated with adverse effects such as tendinopathy, QT interval prolongation, and potential neurological toxicities. Fleroxacin is thus identified as a candidate QTc-prolonging agent.

In sourcing fleroxacin as an active pharmaceutical ingredient, procurement specialists and formulation scientists must prioritize suppliers with validated quality management systems, adherence to current Good Manufacturing Practices (cGMP), and thorough characterization data. Given its experimental classification, regulatory documentation and stability profiles should be rigorously evaluated to ensure compliance and suitability for investigational formulations.